Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Akebia Therapeutics Inc (NASDAQ: AKBA) was $1.55 for the day, down -3.73% from the previous closing price of $1.61. In other words, the price has decreased by -$3.73 from its previous closing price. On the day, 2.53 million shares were traded. AKBA stock price reached its highest trading level at $1.63 during the session, while it also had its lowest trading level at $1.55.
Ratios:
Our analysis of AKBA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.79. For the most recent quarter (mrq), Quick Ratio is recorded 1.80 and its Current Ratio is at 1.94. In the meantime, Its Debt-to-Equity ratio is 5.13 whereas as Long-Term Debt/Eq ratio is at 4.30.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 411317280 and an Enterprise Value of 443881280. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.83 while its Price-to-Book (P/B) ratio in mrq is 9.88. Its current Enterprise Value per Revenue stands at 1.972 whereas that against EBITDA is 13.765.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.35, which has changed by -0.17112297 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is -16.01%, while the 200-Day Moving Average is calculated to be -42.32%.
Shares Statistics:
AKBA traded an average of 4.11M shares per day over the past three months and 2895300 shares per day over the past ten days. A total of 265.23M shares are outstanding, with a floating share count of 256.75M. Insiders hold about 3.25% of the company’s shares, while institutions hold 47.42% stake in the company. Shares short for AKBA as of 1765756800 were 34581801 with a Short Ratio of 8.42, compared to 1763078400 on 35344201. Therefore, it implies a Short% of Shares Outstanding of 34581801 and a Short% of Float of 13.170000000000002.
Earnings Estimates
As of right now, 2.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.0, with high estimates of $0.02 and low estimates of -$0.01.
Analysts are recommending an EPS of between $0.04 and $0.04 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is $0.17, with 2.0 analysts recommending between $0.19 and $0.15.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $63.86M to a low estimate of $45.4M. As of. The current estimate, Akebia Therapeutics Inc’s year-ago sales were $46.5MFor the next quarter, 5 analysts are estimating revenue of $59.33M. There is a high estimate of $67.4M for the next quarter, whereas the lowest estimate is $52.8M.
A total of 5 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $254.4M, while the lowest revenue estimate was $224M, resulting in an average revenue estimate of $239.31M. In the same quarter a year ago, actual revenue was $160.18MBased on 5 analysts’ estimates, the company’s revenue will be $293.03M in the next fiscal year. The high estimate is $313.55M and the low estimate is $258M.
